2019

Benefits of HPV Vaccination in Adolescent Males

Budd Theriot

University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters

Part of the Medical Immunology Commons

Recommended Citation

https://commons.und.edu/pas-grad-posters/157
HPV is the most common sexually transmitted infection in the United States, affecting approximately 75–80% of young adults at some point in their lives, and it is also known to be directly related to several forms of cancer including cervical, vaginal, penile, anal, and oropharyngeal. Vaccination against several high-risk strains of HPV first became available in the U.S. in June of 2006 and has been proven to be effective in creating antibodies against several strains of HPV, potentially decreasing and preventing more than 30,000 new cases of HPV-related cancers each year. Despite this fact, HPV vaccination rates remain low. Although vaccination is recommended for both female and male adolescents, male vaccination rates remain lower than female, likely due to the fact that HPV is most commonly associated with cervical cancer. However, evidence shows that among certain male populations, such as homosexual or related cancer rates may be as high in males as cervical cancer rates in females, demonstrating the potential impact of HPV vaccination in males. Lack of knowledge, and a perceived lack of necessity for male vaccination are substantial barriers for achieving targeted vaccination rates. There is evidence demonstrating that proper education, or simply having a visit with patients, can help to increase patient compliance of receipt of HPV vaccination. Additionally, there is an abundance of unverified information attempting to link HPV vaccination to severe adverse reactions. There is minimal evidence to support such a correlation, but some studies do suggest it. A need for further investigation is warranted.

### Statement of the Problem

It is well established and accepted that HPV can lead to cervical cancer in an adult lifetime. Consequences in males who have HPV are not as known or accepted by the public. Parents of adolescent male patients tend to be more hesitant in agreeing to vaccine their male children.

Additionally, there are many non-verified reports across social media and the internet stating that the HPV vaccine may cause different autoimmune diseases such as Guillain Barre Syndrome or other severe conditions such as postural orthostatic tachycardia syndrome (POTS). It is the responsibility of health care providers to properly educate patients and parents of whom are recommended to receive vaccine against HPV and prevent potentially severe complications later in life. Unfortunately, this is often not what actually happens.

### Research Questions

- In adolescent male patients, does vaccination against human papilloma virus (HPV) significantly decrease incidence of several types of cancers later in life, compared to adolescent males who have not received an hpv vaccine?
- Does vaccination against Human Papilloma Virus cause potentially severe adverse reactions, such as autoimmune diseases?
- Can adequately educating patients, or a patient’s caregiver, lead to an increase in compliance in receiving HPV vaccination in male adolescents?
- Do you want to emphasize?

### Literature Review

There are more than 150 known strains of HPV. Only a few are virulent, those are spread through sexual contact and cause genital warts and can lead to some types of cancer (Centers for Disease Control and Prevention, 2016).

HPV vaccines were first FDA approved in 2006. In the U.S. today there are two HPV vaccines available. They have a similar efficacy, but one only covers two strains of the HPV and the other covers nine strains. (VanWormer, J. J., Bendixsen, C. G., Vickers, E. R., Stokley, S., McNeil, M. 2015). Additionally, there is an abundance of unverified information attempting to link HPV vaccination to severe adverse reactions. There is minimal evidence to support such a correlation, but some studies do suggest it. A need for further investigation is warranted.


### Discussion

- It is estimated that in the United States alone, 14 million persons are infected with HPV annually, and 79 million persons have prevalent infection.
- Since the initial release of the first HPV vaccine in 2006, the vaccine (Gardasil) has been updated to prevent 9 of the more virulent strains of HPV rather than 4 which is what the initial vaccine prevented. Another vaccination option is the bivalent HPV vaccine (Cervarix) which only prevents the high-risk strains 16 and 18, however it may be effective in preventing cancers related to these specific HPV strains.
- According to the CDC, only 49% of adolescents between the ages of 13 and 17 were up to date with their HPV vaccination schedule. This is well short of the goal of 80% vaccination among this age group.
- Increasingly alarming to the information above is the fact that male vaccination rates are even lower than the already low rates in female patients.
- Studies have shown the best seroconversion rates are among adolescents between 11 and 16 years of age and before first sexual encounter.
- Men who have sex with other men are much more likely to be infected with high-risk HPV.
- There is very minimal evidence to suggest that HPV vaccination can cause any autoimmune diseases such as Guillain-Barré syndrome. The majority of the evidence shows no increased risk.
- It is the responsibility of a healthcare provider to provide his/her patients with the most accurate and up-to-date information about all vaccinations.
- Long term side effects as well as prolonged serovaccination must be evaluated to truly gauge the efficacy, safety, and impact HPV vaccination will truly have.

### Applicability to Clinical Practice

This scholarly project was intended to inform and educate parents and clinicians of the importance of HPV vaccination in adolescent male patients, distinguish fact from fiction regarding adverse reactions caused by HPV vaccination, and to identify barriers causing skepticism and hesitancy in receiving HPV vaccination. With society’s growing concerns regarding vaccinations, it is increasingly important to inform patients with the most accurate and up to date information about vaccines.

With increasing education about HPV and HPV vaccination, we can potentially improve these vaccination rates and in do so, decrease rates of HPV related cancers. Hopefully the information provided in scholarly project will aid clinicians to provide patients and parents with the necessary information to make informed decisions on whether to vaccinate their children against Human Papilloma Virus.

### References


### Acknowledgements

First and foremost, I would like to thank my family for their constant patience, dedication, and support in helping me to complete this project. The other individuals who have contributed to this project and the work that they have done have propelled me forward throughout this process, without their support completion of this project would not have been possible. A special thanks also goes to my faculty advisor Professor Jay Metzger PA-C, as well as Professor Daryl Sieg PA-C, for their guidance and assistance in completion of this scholarly project. Last but not least, I would like to thank the faculty members for their constant support, guidance, criticism, and assistance. Without you all, completion of this project would not have been possible.